Follicular Lymphoma

>

Latest News

Exploring Bispecific Antibodies and Targeted Approaches in Follicular Lymphoma
Exploring Bispecific Antibodies and Targeted Approaches in Follicular Lymphoma

September 4th 2024

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.

Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point

August 16th 2024

FDA Approves Epcoritamab in Relapsed/Refractory Follicular Lymphoma
FDA Approves Epcoritamab in Relapsed/Refractory Follicular Lymphoma

June 27th 2024

FDA Approves Liso-Cel for Relapsed/Refractory Follicular Lymphoma
FDA Approves Liso-Cel for Relapsed/Refractory Follicular Lymphoma

May 15th 2024

Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma

March 8th 2024

Latest CME Events & Activities

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
1213141516